icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
76452J9DW35QUqgn
Listen
